Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms

December 2018 Vol 11, No 9 - Conference Correspondent
Download PDF

This study evaluated the in vitro activity of omadacycline against a broad collection of clinical isolates with molecularly characterized tetracycline resistance mechanisms. A total of 167 Gram-positive and Gram-negative clinical isolates from the worldwide SENTRY Antimicrobial Surveillance Program, the vast majority (79%) from the 2016 sampling year, were included in this study.

Against tetracycline-resistant Gram-positive isolates, omadacycline (MIC50/90, 0.12/0.25 µg/mL) and tigecycline (MIC50/90, 0.06/0.25 µg/mL) showed similar results tested against Staphylococcus aureus carrying tet(K). Omadacycline (MIC90, 0.25-2 µg/mL) and tigecycline (MIC90, 0.12-1 µg/mL) showed potent MIC results against Gram-positive isolates carrying tet(L) and/or tet(M). Tetracycline and doxycycline had MIC90 values of ≥8 µg/mL against isolates carrying tet genes, except for doxycycline (MIC50/90, 0.5/0.5 µg/mL) that was active against those carrying tet(K) genes. Against tetracycline-resistant Gram-negative isolates, omadacycline (MIC50/90, 1/4 µg/mL) and tigecycline (MIC50/90, 0.25/0.5 µg/mL) had the lowest MIC results against Gram-negative Enterobacteriaceae isolates carrying tet(B). Omadacycline showed MIC50 results of 2, 4, and 4 µg/mL, respectively, against isolates carrying tet(D), tet(A), and tet(A)+tet(D). Among tetracyclines, omadacycline (MIC50/90, 2/8 µg/mL) and tigecycline (MIC50/90, 0.5/2 µg/mL) demonstrated the lowest MIC results when tested against Gram-negative isolates harboring a combination of other tet genes. Tetracycline and doxycycline were not active (62.5-100.0% resistance) in vitro against Gram-negative Enterobacteriaceae isolates carrying tet genes. These results indicate that omadacycline is not adversely affected against molecularly characterized Gram-positive clinical isolates carrying commonly acquired tet genes.

Source: Mendes RE, et al. IDWeek 2018. Abstract 1377.

Related Items
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Improved Quality of Life in Adults with Acute Bacterial Skin and Skin Structure Infections with Omadacycline or Linezolid Therapy
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: December 27, 2018
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME